Education
About Us
Working with TipRanks
Follow Us
Artelo Biosciences Inc (ARTL)
NASDAQ:ARTL
Total Valuation
Artelo Biosciences has a market cap or net worth of $5.75M. The enterprise value is $6.43M.
Market Cap$5.75M
Enterprise Value$6.43M
Share Statistics
Artelo Biosciences has 1,321,552 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,321,552
Owned by Insiders24.95%
Owned by Institutions<0.01%
Financial Efficiency
Artelo Biosciences’s return on equity (ROE) is -3.44 and return on invested capital (ROIC) is -341.37%.
Return on Equity (ROE)-3.44
Return on Assets (ROA)-2.09
Return on Invested Capital (ROIC)-341.37%
Return on Capital Employed (ROCE)-3.45
Revenue Per Employee0.00
Profits Per Employee-1.64M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Artelo Biosciences is ―. Artelo Biosciences’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value7.17
Price to FCF―
Price to Operating Cash Flow-0.85
PEG Ratio―
Income Statement
In the last 12 months, Artelo Biosciences had revenue of 0.00 and earned -9.83M in profits. Earnings per share was -3.05.
Revenue0.00
Gross Profit0.00
Operating Income-10.11M
Pretax Income-9.83M
Net Income-9.83M
EBITDA-10.11M
Earnings Per Share (EPS)-3.05
Cash Flow
In the last 12 months, operating cash flow was -6.63M and capital expenditures 0.00, giving a free cash flow of -6.63M billion.
Operating Cash Flow-6.63M
Free Cash Flow-6.63M
Free Cash Flow per Share-5.01
Dividends & Yields
Artelo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.31
52-Week Price Change-37.36%
50-Day Moving Average11.80
200-Day Moving Average7.74
Relative Strength Index (RSI)23.91
Average Volume (3m)114.47K
Important Dates
Artelo Biosciences upcoming earnings date is Nov 18, 2025, TBA (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Artelo Biosciences as a current ratio of 1.44, with Debt / Equity ratio of -63.73%
Current Ratio1.44
Quick Ratio1.44
Debt to Market Cap0.00
Net Debt to EBITDA0.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Artelo Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Artelo Biosciences EV to EBITDA ratio is -1.81, with an EV/FCF ratio of -2.19.
EV to Sales0.00
EV to EBITDA-1.81
EV to Free Cash Flow-2.19
EV to Operating Cash Flow-2.19
Balance Sheet
Artelo Biosciences has $2.07M in cash and marketable securities with $896.00K in debt, giving a net cash position of -$1.17M billion.
Cash & Marketable Securities$2.07M
Total Debt$896.00K
Net Cash-$1.17M
Net Cash Per Share-$0.89
Tangible Book Value Per Share$0.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Artelo Biosciences is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$20.00
Price Target Upside359.77% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast4.49%